Medicina
Facultad
Policlinico Umberto I
Roma, ItaliaPublicaciones en colaboración con investigadores/as de Policlinico Umberto I (17)
2024
2023
-
Clinically Driven Revascularization in High-Risk Patients Treated With Ticagrelor Monotherapy After PCI: Insights from the Randomized TWILIGHT Trial
American Journal of Cardiology, Vol. 208, pp. 16-24
-
Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention
JACC: Cardiovascular Interventions, Vol. 16, Núm. 20, pp. 2514-2524
-
Ticagrelor with or without aspirin in high-risk patients with anaemia undergoing percutaneous coronary intervention: a subgroup analysis of the TWILIGHT trial
European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 9, Núm. 4, pp. 328-336
2022
-
Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index
JACC: Cardiovascular Interventions, Vol. 15, Núm. 19, pp. 1948-1960
-
Thalassaemia is paradoxically associated with a reduced risk of in-hospital complications and mortality in COVID-19: Data from an international registry
Journal of Cellular and Molecular Medicine, Vol. 26, Núm. 9, pp. 2520-2528
-
Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI: A Prespecified TWILIGHT Substudy
JACC: Cardiovascular Interventions, Vol. 15, Núm. 3, pp. 282-293
2021
-
Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI
JACC: Cardiovascular Interventions, Vol. 14, Núm. 13, pp. 1434-1446
-
Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR
European Heart Journal, Vol. 42, Núm. 45, pp. 4624-4634
-
Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD
European Heart Journal, Vol. 42, Núm. 45, pp. 4683-4693
2019
-
Ticagrelor with or without aspirin in high-risk patients after PCI
New England Journal of Medicine, Vol. 381, Núm. 21, pp. 2032-2042
2017
-
Empiric Therapy with Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Results from the INCREMENT Cohort
Clinical Infectious Diseases, Vol. 65, Núm. 10, pp. 1615-1623
-
Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study
International Journal of Antimicrobial Agents, Vol. 50, Núm. 5, pp. 664-672
2016
-
A multinational, preregistered cohort study of β-lactam/β-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-β-lactamase-producing enterobacteriaceae
Antimicrobial Agents and Chemotherapy, Vol. 60, Núm. 7, pp. 4159-4169
-
Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: A multinational pre-registered cohort study
Journal of Antimicrobial Chemotherapy, Vol. 71, Núm. 6, pp. 1672-1680
2013
-
Comparative effects of teriparatide and risedronate in glucocorticoid- induced osteoporosis in men: 18-month results of the EuroGIOPs trial
Journal of Bone and Mineral Research, Vol. 28, Núm. 6, pp. 1355-1368
-
Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis
Osteoporosis International, Vol. 24, Núm. 12, pp. 2971-2981